On January 20, Kelun Pharmaceutical (SZ002422, stock price 28.13 yuan, market value 45.05 billion yuan) announced that its subsidiary Kelun Botai's anti-PD-L1 tagolizumab (trade name: Kotel) was approved for combination with cisplatin and gemcitabine for the first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). This is the second indication approved for tagolizumab. At the end of December 2024, the China National Medical Products Administration (NMPA) has approved tagolizumab monotherapy for the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have failed 2 or more lines of chemotherapy for listing in China.

It is worth noting that both among the 20 PD-(L)1 drugs that have been launched in China and in the indication of nasopharyngeal carcinoma, tagolizumab is "late to the party". As a PD-L1 introduced from Kangfang Bio in 2014, why did Kelun Biotech still launch it to the market despite being "late to the party"?

Daily Economic News reporters noticed that as a pharmaceutical company with ADC (antibody conjugate) pipeline as its highlight, Kelun Biotech is also conducting two clinical trials of tagolizumab combined with its core product ruconazole tuzumab. One of them is the first indication of ruconazole tuzumab, triple-negative breast cancer, and the other indication is the non-small cell lung cancer indication that ADC drugs are competing for.

PD-(L)1 "rolls and dies" Kelun Biotech's new drug has just been approved for marketing

When domestic PD-(L)1 has "rolled" to the second half, there are still new drugs approved for marketing.

On the evening of January 20, Kelun Pharmaceutical announced that its subsidiary's anti-PD-L1 tagolizumab (trade name: Ketailai) was approved for marketing by the National Medical Products Administration.

Source: https://finance.eastmoney.com/